share_log

Shattuck Labs | 4: Statement of changes in beneficial ownership of securities-Officer Pandite Arundathy N.

SEC announcement ·  Feb 1 05:10
Summary by Futu AI
Shattuck Labs, Inc.'s Chief Medical Officer, Arundathy N. Pandite, completed a sale of company stock on January 30, 2024. The transaction involved the disposal of 2,920 shares of common stock at a price of $9.99 per share. Following the sale, Pandite's direct holdings in Shattuck Labs amount to 216,360 shares. The sale, which was conducted under transaction code 'F', indicating a payment of exercise price or tax liability by delivering or withholding securities, resulted in a total market value of $29,170.80.
Shattuck Labs, Inc.'s Chief Medical Officer, Arundathy N. Pandite, completed a sale of company stock on January 30, 2024. The transaction involved the disposal of 2,920 shares of common stock at a price of $9.99 per share. Following the sale, Pandite's direct holdings in Shattuck Labs amount to 216,360 shares. The sale, which was conducted under transaction code 'F', indicating a payment of exercise price or tax liability by delivering or withholding securities, resulted in a total market value of $29,170.80.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.